Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cures Act

- PMLiVE

Pfizer builds gap between pharma and consumer health units

Its consumer health division will become a standalone unit after lack of buyer interest

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

Reaching the new influencers

With payers looking increasingly to real-world data, and to differentiation beyond this data through outcomes commitment and the provision of beyond the pill services, there’s never been a better time...

- PMLiVE

Real-world data finds patients feel better on Entresto, says Novartis

Patients on Entresto reported an “early, statistically significant improvement in health status”

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

- PMLiVE

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

- PMLiVE

Alkermes slumps as FDA turns down depression drug

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

- PMLiVE

Health on instalment

Can US-style financial engineering underwrite ultra-expensive gene therapies?

- PMLiVE

Seattle Genetics claims key US approval for Adcetris

Becomes the first new treatment for advanced Hl in more than 40 years

- PMLiVE

FDA approves another home genetic testing service

23andMe’s kit will check for an increased risk of certain cancers developing

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links